Completed PHASE3 INTERVENTIONAL 3-arm NCT04593940

Immune Modulators for Treating COVID-19 (ACTIV-1 IM)

Randomized Master Protocol for Immune Modulators for Treating COVID-19

Sponsor: Biomedical Advanced Research and Development Authority

Conditions Covid19

Interventions Abatacept Infliximab Remdesivir cenicriviroc (closed to enrollment as of 3-Sep-2021)

Updated 20 times since 2020 Last updated: Sep 14, 2023 Started: Oct 15, 2020 Primary completion: Jan 30, 2022 Completion: Mar 5, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Covid19, this trial is completed. The trial is conducted by Biomedical Advanced Research and Development Authority and has accumulated 20 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2023 — Jul 2024 [monthly]

Completed PHASE3
May 2023 — Oct 2023 [monthly]

Completed PHASE3

▶ Show 15 earlier versions

Oct 2022 — May 2023 [monthly]

Completed PHASE3
Jun 2022 — Oct 2022 [monthly]

Completed PHASE3
Apr 2022 — Jun 2022 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2022 — Apr 2022 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Nov 2021 — Feb 2022 [monthly]

Recruiting PHASE3
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE3
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE3
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE3
May 2021 — Jun 2021 [monthly]

Recruiting PHASE3
Apr 2021 — May 2021 [monthly]

Recruiting PHASE3
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE3
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE3

First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biomedical Advanced Research and Development Authority
Daniel Benjamin
National Center for Advancing Translational Sciences (NCATS)

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alma, United States , Annapolis, United States , Bahía Blanca, Argentina , Baltimore, United States , Belo Horizonte, Brazil , Boston, United States , Brasília, Brazil , Brooklyn, United States , Buenos Aires, Argentina , Buffalo, United States and 64 more locations